Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates

This article was originally published on Nasdaq

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring i